Members of the team spoke with the News about their experiences performing the BATMAN procedure and its future implications.

Dr. Ron Aviles explains available procedures and recovery time for those with heart and vascular conditions. Sponsored by Overlake Medical Center and Clinics.

In addition, before the development of prosthetic mitral-valve replacement, pure or predominant mitral regurgitation could not consistently be relieved by operation, and although it was clear that ...

The BATMAN (Basilica Technique with MitraClip for Anatomically Nonconforming) procedure is a novel transcatheter approach designed to treat severe mitral regurgitation (MR) in patients who are poor ...

For patients suffering from severe heart disease, the thought of getting an open bypass surgery may be terrifying—and it’s ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Chronic significant mitral regurgitation (csMR) was defined as a long-existing ... these patients should be monitored regularly during anticoagulant therapy. Mitral valve repair or replacement could ...

is noninferior to mitral valve (MV) surgery in patients with heart failure and secondary mitral regurgitation at 1 year. Patient selection is key for success of any surgical or percutaneous MV ...

Valve regurgitation remains the principal pathology of the ... was initially designed for the treatment of secondary mitral regurgitation (MR); the results showed a 95% MR reduction (MR ≤2) sustained ...

A transthoracic echocardiography was performed, which showed preservation of the ventricular cavity size and function, mildly increased biatrial size and severe mitral valve regurgitation, without ...

repair with the MitraClip device in patients at high risk for MV surgery treated in the Endovascular Valve Edge-to-Edge Repair (EVEREST) II High Risk Study (HRS). Methods Patients with mitral ...

For one, the patients in the RESHAPE-HF2 trial had less severe mitral valve regurgitation than did those in the MITRA-FR and COAPT trials, although they demonstrated more severe symptoms. Even though ...